In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand11C-PK11195

Journal of Nuclear Medicine

Volumn 55, Issue 6, 2014, Pages 939-944

  Rissanen, Eero ^a,b   Tuisku, Jouni ^a   Rokka, Johanna ^a   Paavilainen, Teemu ^c   Parkkola, Riitta ^a,d   Rinne, Juha O ^a   Airas, Laura ^b  

^a TURKU PET CENTRE   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c HOSPITAL DISTRICT OF SOUTHWEST FINLAND   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Disease progression; Microglia; Multiple sclerosis; PET

Indexed keywords

CELL PROTEIN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; TRANSLOCATOR PROTEIN; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; CARBON; ISOQUINOLINE DERIVATIVE; LIGAND; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; TSPO PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENCEPHALITIS; EXPANDED DISABILITY STATUS SCALE; FEMALE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; MALE; MICROGLIA; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THALAMUS; WHITE MATTER; WHITE MATTER LESION; BRAIN; CASE CONTROL STUDY; DIAGNOSTIC USE; DISEASE COURSE; METABOLISM; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; BRAIN; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; ISOQUINOLINES; LIGANDS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, GABA;

EID: 84901251800     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.131698     Document Type: Article

References (33)

1. Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol. 2009;5:672-682.
2. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122:1180-1188.
3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907-911.
4. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175-1189.
5. Brück W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol. 1995;38:788-796.
6. Moll NM, Rietsch AM, Thomas S, et al. Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol. 2011;70:764-773.
7. Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477-493.
8. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128:2705-2712. (Pubitemid 41552953)
9. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8:647-656.
10. Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. 2001;50:646-657. (Pubitemid 33021923)
11. Filippi M, Rocca MA, Barkhof F, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2012;11:349-360.
12. Filippi M, Iannucci G, Cercignani M, Assunta Rocca M, Pratesi A, Comi G. A quantitative study of water diffusion in multiple sclerosis lesions and normal-appearing white matter using echo-planar imaging. Arch Neurol. 2000;57:1017-1021. (Pubitemid 30452507)
13. Mistry N, Tallantyre EC, Dixon JE, et al. Focal multiple sclerosis lesions abound in 'normal appearing white matter'. Mult Scler. 2011;17:1313-1323.
14. Ching AS, Kuhnast B, Damont A, Roeda D, Tavitian B, Dolle F. Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging. 2012;3:111-119.
15. Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. 2000;123:2321-2337.
16. 11C-(R)-PK11195 brain studies. J Nucl Med. 2007;48:158-167.
17. Politis M, Giannetti P, Su P, et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology. 2012;79:523-530.
18. Ratchford JN, Endres CJ, Hammoud DA, et al. Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol. 2012;259:1199-1205.
19. Heiss WD, Habedank B, Klein JC, et al. Metabolic rates in small brain nuclei determined by high-resolution PET. J Nucl Med. 2004;45:1811-1815. (Pubitemid 47618436)
20. de Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol. 2007;52:1505-1526. (Pubitemid 46646401)
21. 11C-raclopride with high-resolution positron emission tomography. J Cereb Blood Flow Metab. 2011;31:155-165.
22. 11C-(R)-PK11195 scans on the high resolution research tomograph (HRRT) [abstract]. Neuroimage. 2008;41(suppl 2):T65.
23. Schmidt P, Gaser C, Arsic M, et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage. 2012;59:3774-3783.
24. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273-289. (Pubitemid 34852226)
25. 11C-PK11195 brain PET studies. J Cereb Blood Flow Metab. 2012;32:1600-1608.
26. 11C]PK11195 binding images: plasma input versus reference tissue parametric methods. Neuroimage. 2007;35:1473-1479.
27. Debruyne JC, Versijpt J, Van Laere KJ, et al. PET visualization of microglia in multiple sclerosis patients using 11C-PK11195. Eur J Neurol. 2003;10:257-264. (Pubitemid 36609480)
28. Versijpt J, Debruyne JC, Van Laere KJ, et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler. 2005;11:127-134. (Pubitemid 40403248)
29. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology. 1991;180:467-474.
30. Wu C, Zhu J, Baeslack J, et al. Longitudinal positron emission tomography imaging for monitoring myelin repair in the spinal cord. Ann Neurol. 2013;74:688-698.
31. Rissanen E, Virta JR, Paavilainen T, et al. Adenosine A2A receptors in secondary progressive multiple sclerosis: a [C]TMSX brain PET study. J Cereb Blood Flow Metab. 2013;33:1394-1401.
32. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1-5.
33. Kreisl WC, Jenko KJ, Hines CS, et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab. 2013;33:53-58.